Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AssigneesGanymed Pharmaceuticals AG, TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Unive
InventorsUgur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
Life of this patent
Estimating the term…
Abstract
The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
Claims39
A method of treating or preventing pancreatic cancer in a patient comprising administering to the patient (i) an antibody having the ability of binding to CLDN18.2 and (ii) an agent stabilizing or increasing expression of CLDN18.2.
A method of treating or preventing cancer in a patient comprising administering to the patient (i) an antibody having the ability of binding to CLDN18.2 and (ii) gemcitabine.
A medical preparation for treating or preventing pancreatic cancer comprising (i) an antibody having the ability of binding to CLDN18.2 and (ii) an agent stabilizing or increasing expression of CLDN18.2.
A medical preparation comprising (i) an antibody having the ability of binding to CLDN18.2 and (ii) gemcitabine.
Dependencies are inferred from the claim text.